Companies: 10,795·Total market cap: $144.5T
Adaptimmune Therapeutics plc

Adaptimmune Therapeutics plc

ADAPNASDAQHealthcare
$0.05
$-0.00(-3.00%)
Market Cap$75157679
P/E Ratio—
52W High$0.86
52W Low$0.0202
Overview
Foreign Private Issuer · Files 20-F / 6-K

Adaptimmune Therapeutics plc (ADAP) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001621227 · ADAP · NASDAQ · as of Jun 9, 2026

Filing snapshot

808
Total Filings
RW
Latest Form
2026-04-22
Most Recent
2015
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001621227 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2025-03-24
Fiscal Year End
Mar 24, 2025
Accession No.
0001558370-25-003544
Primary Document
adap-20241231x10k.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001621227 · Accession 0001558370-25-003544

Latest Key Filings

6-KQuarterly Report
6-K
2015-12-17
View 6-K on SEC
8-KCurrent Report
8-K
2025-10-20Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
RWRW
RW
2026-04-22
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-02-17
View
EFFECTEFFECT
EFFECT
2025-11-14
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2025-11-14
View
424B3424B3
424B3
2025-11-13
View
15-12G15-12G
15-12G
2025-11-13
View
S-8 POSS-8 POS
S-8 POS
2025-10-28
View
S-8 POSS-8 POS
S-8 POS
2025-10-28
View
S-8 POSS-8 POS
S-8 POS
2025-10-28
View
POS AMPOS AM
POS AM
2025-10-28
View
2525
FORM 25
2025-10-28
View
8-KCurrent Report
8-K
2025-10-20
View
3Initial Statement of Beneficial Ownership
OWNERSHIP DOCUMENT
2025-10-08
View
8-KCurrent Report
8-K
2025-09-26
View
8-KCurrent Report
8-K
2025-09-12
View
Showing 1–15 of 485 filingsForm 4 / 144 hidden· 808 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001621227  |  Exchange: NASDAQ · Healthcare

Adaptimmune Therapeutics plc (NASDAQ: ADAP) has submitted 808 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2015. As a Healthcare sector company with CIK 0001621227, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Adaptimmune Therapeutics plc's most comprehensive regulatory disclosure. The most recent Adaptimmune Therapeutics plc 10-K was filed on 2025-03-24 for fiscal year ending 2025. Historical ADAP 10-K annual reports are available from 2014 through 2025.

Investors researching Adaptimmune Therapeutics plc SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09
Related Companies SEC Filings — Healthcare
ANL SEC Filings →THAR SEC Filings →APLM SEC Filings →BLRX SEC Filings →LPCN SEC Filings →LNAI SEC Filings →OSRH SEC Filings →MBRX SEC Filings →
→ ADAP Financials→ ADAP Earnings→ ADAP Insider Trades

Frequently Asked Questions

ADAP SEC Filings · 8 questions

Adaptimmune Therapeutics plc (ADAP) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 808 filings and access original documents at no cost. Adaptimmune Therapeutics plc's CIK is 0001621227.

ADAP SEC filingsAdaptimmune Therapeutics plc SEC documentsfind ADAP 10-K